FDA Approves Ocrelizumab for Pediatric Relapsing MS
The FDA approval makes ocrelizumab a new treatment option for children aged 10 years and older with relapsing-remitting multiple sclerosis. Medscape Medical News
Original Source
Read the full article at Medscape →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.